Speaker for Nursing Conferences 2019- Ruechuta Molek

Title: Factors Predicting Hospital Stays of Patients with Advanced Cancer Receiving Morphine and its Derivatives

Ruechuta Molek

Chulabhorn Hospital, Thailand

Biography

Ms. Ruechuta Molek, a head nurse of Inpatient Unit at Chulabhorn Hospital, is interested in cancer patients’ quality of life. She has obtained Master degree in Adult Nursing in 2014 with experiences in research studies on advanced cancer.

Abstract

Cancer, a horrible disease, kills a number of patients at the early rank. Victims have to face with not only the disease itself but also its metastasis and treatment. Consequently, it disturbs patients’ physical, financial and psychological problems as well as spiritual status with symptoms of pain, dyspnea, fatigue, loss of appetite and weight loss. In addition, they have much concern about their appearance and expenditure. Though advanced cancer-related symptoms are uncontrollable in these patients, painkiller and palliative treatments in the hosptial would help to alleviate their despair
Morphine and its derivatives play a crucial role in pain management, particularly in patients with advanced cancer. However, the efficacy depends on pathophysiology of the disease, intensity of pain, and patient background other than its pharmacokinetic and pharmacodynamics. Considerably, the administration of morphine is not without adverse effects; namely, respiratory depression, hypotension, nausea, vomiting, itching, incontinence of urine, constipation, dizziness, drowsiness, myoclonus, delirium and euphoria. In addition, patients with severe dehydration, systemic infection and multiple organs failure worsen the event.
As a result, healthcare providers have to organize an effective monitoring for proper dosage and patients’ easiness till the end of their lives.  Since intravenous morphine has become an interesting topic in the terminal stage of advanced cancer patients, investigators would like to know the related-factors that can determine their hospital stays during the administration of intravenous morphine and its derivatives.